Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

← catalyst calendar

NCT06168409 · results posted

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
218actual
Sites
102
Countries
Argentina, Australia, Belgium +19

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-03-01actualWhen the study began enrolling
Primary completion2025-08-17actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-08-17actualThe whole study's end, after follow-up
First posted2023-12-13actualWhen this record first appeared on the registry
Results posted2026-08-06actualWhen the sponsor posted results to the registry
Record updated2026-08-06actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Resistant Hypertension

Interventions

  • Drug: Baxdrostat — also filed as CIN-107
  • Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF
Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy
measured Baseline to week 12

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2024-05-29 · 1.0 MB · Prot_004.pdf
Statistical Analysis Planposted 2025-07-29 · 891 KB · SAP_005.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed